Guardion Health Sciences Reports 2019 Year End Results and Provides Corporate Update and Overview

Guardion Health Sciences Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

Guardion Health Sciences Receives $3.5 Million from Exercise of Warrants

Guardion Health Sciences Selected by Malaysian Listed Company to Develop an Immuno-Supportive Formula

Guardion® Announces Development of Unique Immuno-Supportive Complex Targeting Upper Respiratory Tract Infections

Guardion Health Sciences, Inc. Reports Results for the Three and Nine Months Ended September 30, 2019

Guardion Health Sciences Closes $8.4 Million Underwritten Public Offering

Guardion® Appoints Experienced Executive to Lead Development and Expansion of Recently-Acquired NutriGuard Business Line

Guardion Health Sciences Announces Pricing of $8.4 Million Underwritten Public Offering

Guardion® Receives approval from USPTO for expanded claims for its Proprietary Medical Device, the MAPCAT SF

Guardion® Announces Statistically Significant Blood Assay Study Results

Guardion Health Sciences Acquires the NutriGuard Brand of Products

Guardion Launches VectorVision CSV-2000 Standardized Contrast Sensitivity Test

Guardion Health Sciences Announces an Increase in the Pricing of its Previously Announced Underwritten
Public Offering

Guardion Health Sciences Closes $5.8 Million Underwritten Public Offering

Guardion Health Sciences Announces Pricing of $5.2 Million Underwritten Public Offering

Guardion Health Sciences Reports June 30, 2019 Interim Results of Operations

Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the European Union

Guardion’s Proprietary Medical Device, the MapcatSF®, Receives Patent from the Hong Kong Patents Registry

Guardion Launches Second Ocular Health Formula ‘GlaucoCetin’

Guardion’s Lumega-Z Formula Associated with Substantial Clinical Improvement in Patients Contrast Sensitivity Visual Function (CSF) vs AREDS 2

Guardion’s Lumega-Z Formula Associated with Improved Vision in Patients with Severe Glaucoma

Guardion Health Sciences, Inc. Receives Official Trademark Registrations in China

Guardion Health Sciences, Inc. Announces Closing of Initial Public Offering

Results of Lumega-Z Data to be Presented at ARVO

Guardion Health Sciences, Inc. Announces Pricing of Initial Public Offering

Guardion Health Sciences Receives Methods Patents to Standardize Vision Testing

Guardion Health Sciences Exhibiting at Caribbean Eye Meeting

Guardion Health Sciences Closes $5 Million Common Equity Financing

Guardion Health Sciences acquires VectorVision

Guardion Health Sciences announces completion of Series B funding round, raising over $3 million

International Carotenoid Society honors Advisory Board Members with Fellowship Awards

Guardion Health Sciences signs Letter of Intent to acquire VectorVision

Guardion Health Sciences, Inc. completes registration with SEC, becomes a Public Reporting Company

Guardion Health Sciences Medical Advisory Board Member Receives Prestigious Award For Excellence In Ophthalmology Research And Service

Guardion Health Sciences receives patent for its diagnostic device, the MapcatSF

P Dee G Stephenson, M.D. joins Guardion Health Sciences Medical Advisory Board

Bridgitte Shen Lee, O.D. joins Guardion Health Sciences Medical Advisory Board

Guardion Health Sciences Files Form S-1 Registration Statement under the Securities Act of 1933

Macular pigment specialists, Guardion Health Sciences appoints Gordon Bethwaite as Vice President

Col (R) Donald A. Gagliano, MD, MHA, FACHE, CPC joins Guardion’s Science Advisory Board

Macular Carotenoids Conference 2013

Professors Bone and Landrum honored at the Macular Carotenoids & AMD Conference 2011 in Cambridge, UK.

GHS Scientists to Present at the Macular Carotenoids & AMD Conference 2011